Shilcap 500mg Tablet

About

Shilcap 500mg Tablet contains Capecitabine, an oral fluoropyrimidine carbamate that acts as an antimetabolite antineoplastic agent. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) primarily within tumor cells, where it exerts its cytotoxic effects. This selective activation minimizes systemic exposure to 5-FU, potentially reducing systemic toxicity while maximizing drug concentration at the tumor site. Capecitabine interferes with DNA synthesis and inhibits cell proliferation, leading to apoptosis in rapidly dividing cancer cells. It is a cornerstone in the treatment of various solid tumors, often used in both adjuvant and metastatic settings to improve patient outcomes.

The mechanism involves three enzymatic steps, with the final conversion to 5-FU catalyzed by thymidine phosphorylase, an enzyme often found at higher levels in tumor tissues than in normal tissues. This targeted approach makes Shilcap an effective and convenient oral chemotherapy option for eligible patients.

Uses

• Metastatic colorectal cancer
• Adjuvant colorectal cancer
• Metastatic breast cancer
• Advanced gastric cancer

Directions For Use

Take orally with water, usually within 30 minutes after a meal. Follow your doctor's prescribed dosage and schedule strictly.

Benefits

• Oral administration offers patient convenience.
• Targeted conversion to active drug in tumor cells.
• Effective against various solid tumors.
• Part of established chemotherapy regimens.
• May improve disease-free survival in adjuvant settings.
• Potentially reduced systemic toxicity compared to IV 5-FU.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Stomatitis
• Fatigue
• Abdominal pain
• Anorexia
• Constipation
• Dermatitis
• Hyperbilirubinemia
• Myelosuppression (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol due to potential for increased gastrointestinal irritation and liver strain during chemotherapy.
• Pregnancy - Contraindicated. Capecitabine can cause fetal harm. Use effective contraception during treatment and for a period after.
• Breastfeeding - Contraindicated. It is unknown if capecitabine is excreted in human milk; discontinue breastfeeding due to potential for serious adverse reactions.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary; monitor liver function closely.
• Kidney - Use with caution in patients with renal impairment. Dose adjustments are typically required based on creatinine clearance.
• Lung - Generally not a primary concern, but monitor for any new or worsening respiratory symptoms, though severe lung toxicity is rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.